John Behm
Family Medicine · Wexford, PANPI 1437151677
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $884 and has fallen 98.1% since, to $17 in 2025.
Across 151 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$394
- AbbVie$253
- GSK$218
- Biohaven Pharmaceuticals, Inc.$113
- E.r. Squibb & Sons, L.L.C.$104
- Pfizer$102
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,15699%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $394 |
| AbbVie | 19 | $253 |
| GSK | 15 | $218 |
| Biohaven Pharmaceuticals, Inc. | 8 | $113 |
| E.r. Squibb & Sons, L.L.C. | 6 | $104 |
| Pfizer | 7 | $102 |
| Kowa Pharmaceuticals America, Inc. | 6 | $94 |
| Amarin Pharma, Inc. | 5 | $63 |
| Otsuka America Pharmaceutical, Inc. | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $60 |
| Amgen(2 entities) | 4 | $59 |
| Alkermes, Inc. | 3 | $58 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Protega Pharmaceutials Inc | 3 | $51 |
| Lilly USA, LLC | 3 | $50 |
| Corium, LLC | 3 | $48 |
| Novartis | 2 | $46 |
| Abbott | 3 | $42 |
| Johnson & Johnson | 2 | $37 |
| Neos Therapeutics, LP | 2 | $30 |
| Gilead | 2 | $29 |
| Medtronic | 2 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Inari Medical, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Merck | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Nevro Corp. | 1 | $14 |
| Optinose US, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $11 |
How this compares
$2,188 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 12 | $155 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Wexford
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.